Literature DB >> 8655150

An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine.

D Marez1, M Legrand, N Sabbagh, J M Lo-Guidice, P Boone, F Broly.   

Abstract

The identification of a novel CYP2D6 allele from a healthy Caucasian poor metabolizer was achieved by using a previously described polymerase chain reaction/single-strand conformation polymorphism strategy. Among the four point mutations that this allele carries, a missense mutation in exon 1 (212 G-->A or D6-H) seems to be responsible for the loss of CYP2D6 function. Although the mutation D6-H has a low prevalence in a randomly selected population of healthy Caucasians, its identification should further increase the phenotype prediction rate by genotyping.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8655150     DOI: 10.1007/bf02281880

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  19 in total

1.  Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population.

Authors:  M L Dahl; I Johansson; M P Palmertz; M Ingelman-Sundberg; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1992-01       Impact factor: 6.875

2.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

Authors:  M Heim; U A Meyer
Journal:  Lancet       Date:  1990-09-01       Impact factor: 79.321

3.  An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis.

Authors:  F Broly; D Marez; N Sabbagh; M Legrand; S Millecamps; J M Lo Guidice; P Boone; U A Meyer
Journal:  Pharmacogenetics       Date:  1995-12

4.  A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency.

Authors:  F Broly; D Marez; J M Lo Guidice; N Sabbagh; M Legrand; P Boone; U A Meyer
Journal:  Hum Genet       Date:  1995-11       Impact factor: 4.132

5.  CYP2D6 genotype determination in the Danish population.

Authors:  K Brøsen; P N Nielsen; K Brusgaard; L F Gram; K Skjødt
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon.

Authors:  B Evert; E U Griese; M Eichelbaum
Journal:  Pharmacogenetics       Date:  1994-10

Review 7.  Pharmacogenetic phenotyping and genotyping. Present status and future potential.

Authors:  F J Gonzalez; J R Idle
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447

Review 8.  Clinical implications of genetic polymorphism in drug metabolism.

Authors:  G T Tucker
Journal:  J Pharm Pharmacol       Date:  1994-05       Impact factor: 3.765

9.  A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.

Authors:  B Evert; E U Griese; M Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-10       Impact factor: 3.000

10.  Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.

Authors:  R Saxena; G L Shaw; M V Relling; J N Frame; D T Moir; W E Evans; N Caporaso; B Weiffenbach
Journal:  Hum Mol Genet       Date:  1994-06       Impact factor: 6.150

View more
  5 in total

1.  Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes.

Authors:  T Kubota; Y Yamaura; N Ohkawa; H Hara; K Chiba
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

Review 2.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 3.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 4.  Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and the European Society for Pharmacogenomics and Personalized Therapy.

Authors:  Victoria M Pratt; Larisa H Cavallari; Andria L Del Tredici; Andrea Gaedigk; Houda Hachad; Yuan Ji; Lisa V Kalman; Reynold C Ly; Ann M Moyer; Stuart A Scott; R H N van Schaik; Michelle Whirl-Carrillo; Karen E Weck
Journal:  J Mol Diagn       Date:  2021-06-10       Impact factor: 5.341

5.  Methodology for clinical genotyping of CYP2D6 and CYP2C19.

Authors:  Beatriz Carvalho Henriques; Avery Buchner; Xiuying Hu; Yabing Wang; Vasyl Yavorskyy; Keanna Wallace; Rachael Dong; Kristina Martens; Michael S Carr; Bahareh Behroozi Asl; Joshua Hague; Sudhakar Sivapalan; Wolfgang Maier; Mojca Z Dernovsek; Neven Henigsberg; Joanna Hauser; Daniel Souery; Annamaria Cattaneo; Ole Mors; Marcella Rietschel; Gerald Pfeffer; Stacey Hume; Katherine J Aitchison
Journal:  Transl Psychiatry       Date:  2021-11-22       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.